KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI Trial.

Robert F Storey, John Deanfield, Stefan James, Ramzi A Ajjan, Niclas Eriksson, David Erlinge, Mark de Belder, Chris P Gale, Azfar Zaman, Robin Hofmann, Linda Mellbin, Kasper Andersen, Yunyun Jiang, Peter A Johansson, Wilhelm Ridderstråle, Anna Maria Langkilde, Ehsan Parvaresh Rizi, Jonas Oldgren, Darren K McGuire

J Am Heart Assoc 14(15) e040327

PMID40728174
PMCIDPMC12449975
DOI10.1161/JAHA.124.040327
发表日期2025-07-29
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Dapagliflozin improved cardiometabolic outcomes following myocardial infarction in patients without prior type-2 diabetes (T2DM) in the DAPA-MI (dapagliflozin in patients with myocardial infarction) trial. The effect of glycemic status and body mass index (BMI) post-myocardial infarction requires elucidation. METHODS: Participants with T2DM diagnosis, without baseline hemoglobin A1c, or not receiving any study medication, were excluded. Eligible participants were categorized, according to baseline hemoglobin A1c, as normoglycemic (<5.7% [39 mmol/mol]) or prediabetes (5.7 to <6.5% [48 mmol/mol]) and according to baseline BMI (<25, 25 to <30, and ≥30 kg/m2). Hazard ratios (HRs) with 95% CIs and 1-year Kaplan-Meier rates were determined for new-onset T2DM (investigator-reported or hemoglobin A1c ≥6.5%) and New York Heart Association symptom classification during follow-up. RESULTS: Of 4017 DAPA-MI participants, 3425 were eligible. In 1926 with baseline normoglycemia, new-onset T2DM occurred in 0.6% and 1.6% assigned to dapagliflozin and placebo, respectively (hazard ratio, 0.40 [95% CI, 0.15-1.03]); in 1499 with prediabetes at baseline, new-onset T2DM occurred in 10.1% and 13.1%, respectively (hazard ratio, 0.74 [05% CI, 0.55-0.99]; P interaction 0.23). One-year absolute risk reduction for new-onset T2DM was 8.1% in those with both prediabetes and BMI ≥30. Dapagliflozin reduced the occurrence of New York Heart Association class III-IV symptoms, with greater effect in those with prediabetes versus normoglycemia (P interaction 0.009). One-year absolute risk reduction for New York Heart Association class III-IV symptoms was 10.0% in those with both prediabetes and BMI ≥30. CONCLUSIONS: Dapagliflozin reduced the occurrence of new-onset T2DM following myocardial infarction, regardless of baseline hemoglobin A1c or BMI. Dapagliflozin provided greater reduction in heart failure symptom burden in those with prediabetes compared with normoglycemia.

KM 提取结果

2 个 Figure · 12 个 KM 面板

进入结果中心
KM Figure6 个面板

Figure 3

Figure 3. Cumulative probability of new‐onset type‐2 diabetes occurring during follow‐up in dapagliflozin and placebo groups according to baseline HbA1c or body mass index. New‐onset type‐2 diabetes in (A) the whole subanalysis cohort and (B‐F) subgroups of this cohort with the following baseline characteristics: (B) HbA1c < 5.7%, (C) HbA1c 5.7 to < 6.5%, (D) BMI < 25, (E) BMI 25 to < 30, and (F) BMI ≥30. BMI indicates body mass index; HbA1c, hemoglobin A1c; 1‐yr KM%, Kaplan–Meier cumulative incidence at 1 year; and Dapa, dapagliflozin.

A

cumulative probability of new-onset type-2 diabetes

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

cumulative probability of new-onset type-2 diabetes

Figure 3 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

cumulative probability of new-onset type-2 diabetes

Figure 3 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:frequent upward jumps
查看结果
D

cumulative probability of new-onset type-2 diabetes

Figure 3 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
E

cumulative probability of new-onset type-2 diabetes

Figure 3 · Panel E

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel E 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
F

cumulative probability of new-onset type-2 diabetes

Figure 3 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure6 个面板

Figure 6

Figure 6. Cumulative probability of New York Heart Association class III to IV symptoms occurring during follow‐up in dapagliflozin and placebo groups according to baseline HbA1c or body mass index. NYHA class III‐IV symptoms in (A) the whole subanalysis cohort and (B‐F) subgroups of this cohort with the following baseline characteristics: (B) HbA1c < 5.7%, (C) HbA1c 5.7 to < 6.5%, (D) BMI < 25, (E) BMI 25 to < 30, and (F) BMI ≥30. BMI indicates body mass index; 1‐yr KM% indicates Kaplan–Meier cumulative incidence at 1 year; Dapa, dapagliflozin; HbA1c, hemoglobin A1c; and NYHA, New York Heart Association.

A

NYHA class III-IV symptoms

Figure 6 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

NYHA class III-IV symptoms

Figure 6 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

NYHA class III-IV symptoms

Figure 6 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:short span
查看结果
D

NYHA class III-IV symptoms

Figure 6 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
E

NYHA class III-IV symptoms

Figure 6 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
F

NYHA class III-IV symptoms

Figure 6 · Panel F

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel F 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT diagram of the subanalyses cohort. CONSORT indicates Consolidated Standards of Reporting Trials; DAPA‐MI, dapagliflozin in patients with myocardial infarction; DM, diabetes; HbA1c, hemoglobin A1c; and IMP, investigational medicinal product (study medication).
非 KM Figure
Figure 2Figure 2. New‐onset type‐2 diabetes occurring during follow‐up in dapagliflozin and placebo groups according to baseline HbA1c or body mass index. Bars represent percentage of subjects with events. BMI indicates body mass index; HbA1c, hemoglobin A1c; HR, hazard ratio; and T2DM, type‐2 diabetes. * P <0.05; ** P <0.01.
非 KM Figure
Figure 4Figure 4. Mean change in HbA1c values during follow‐up according to treatment group in (A) the whole cohort, (B) participants with normoglycemia at baseline, and (C) prediabetes at baseline. Data are least‐squares mean and error bars show 95% CIs of estimates. Dapa indicates dapagliflozin; and HbA1c, hemoglobin A1c. ** P <0.01, **** P <0.0001.
非 KM Figure
Figure 5Figure 5. New York Heart Association heart failure symptoms of (A) class II to IV or (B) class III to IV occurring during follow‐up in the dapagliflozin and placebo groups according to baseline HbA1c or body mass index. Bars represent percentage of subjects with events. BMI indicates body mass index; CI, confidence intervals; HbA1c, hemoglobin A1c; HR, hazard ratio; and NYHA, New York Heart Association. * P <0.05, ** P <0.01, **** P <0.0001.
非 KM Figure